title: Current clinical development of PI3K pathway inhibitors in glioblastoma.
abstract: Glioblastoma (GBM) is the most common and lethal primary malignant tumor of the central nervous system, and effective therapeutic options are lacking. The phosphatidylinositol 3-kinase (PI3K) pathway is frequently dysregulated in many human cancers, including GBM. Agents inhibiting PI3K and its effectors have demonstrated preliminary activity in various tumor types and have the potential to change the clinical treatment landscape of patients with solid tumors. In this review, we describe the activation of the PI3K pathway in GBM, explore why inhibition of this pathway may be a compelling therapeutic target for this disease, and provide an update of the data on PI3K inhibitors in clinical trials and from earlier investigation.
authors.affiliation: Center For Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. pwen@partners.org
authors.forename: Patrick Y
authors.initials: PY
authors.lastname: Wen
authors.forename: Eudocia Q
authors.initials: EQ
authors.lastname: Lee
authors.forename: David A
authors.initials: DA
authors.lastname: Reardon
authors.forename: Keith L
authors.initials: KL
authors.lastname: Ligon
authors.forename: W K
authors.initials: WK
authors.lastname: Alfred Yung
mesh_terms: D001932:Brain Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005909:Glioblastoma / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D000081082:Phosphoinositide-3 Kinase Inhibitors; D015398:Signal Transduction / Q000187:drug effects*
chemical_list: D004791:Enzyme Inhibitors; D000081082:Phosphoinositide-3 Kinase Inhibitors